RBC Capital Markets will be the sole lead manager for the Offering, and the co-managers will be Needham & Company, LLC, Lazard Capital Markets LLC, Canaccord Adams Inc. and Susquehanna Financial Group, LLLP.
When available, a copy of the U.S. preliminary prospectus may be obtained from RBC Capital Markets Corporation, Attention: Prospectus Department, One Liberty Plaza, 165 Broadway, New York, New York, U.S.A., 10006, or from the U.S. Securities and Exchange Commission at www.sec.gov. When available, a copy of the Canadian preliminary prospectus may be obtained from RBC Capital Markets by calling (416) 842-5345 or from the Canadian Securities Administrators at www.sedar.com.
In the United States, a registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. In Canada, a preliminary prospectus relating to these securities has been filed with the Canadian provincial securities regulatory authorities. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective and a receipt for a final prospectus is issued by the Canadian provincial securities regulatory authorities.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Offering will be made only by means of a prospectus.
About OncoGenex
OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex currently has three product candidates in development: OGX-011, OGX-427 and OGX-225. These product candidates are designed to selectively inhibit the production of proteins that are associated with treatment resistance and that are over-produced in response to a variety of cancer treatments. OncoGenex' aim in targeting these particular proteins is to disable the tumor cell's adaptive defenses, render the tumor cells susceptible to attack with a variety of cancer therapies including chemotherapy, and facilitate tumor cell death.
CONTACT: CNW - 12/13/2006
Source: OncoGenex Technologies Inc.
